Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.
Cureus – January 01, 2025
Source: PubMed
Summary
Scientists are exploring psilocybin, the active compound in magic mushrooms, as a potential treatment for OCD. This protocol outlines a groundbreaking investigation into how psilocybin affects brain function and compulsive behaviors. Researchers will study participants with OCD using brain imaging and behavioral tests to understand if and how this psychedelic compound might help reduce obsessive-compulsive symptoms.
Abstract
[This corrects the article DOI: 10.7759/cureus.78171.].
Authors
Sorcha O'Connor
Kate Godfrey
Sara Reed
Joseph Peill
Cyrus Rohani-Shukla
Mairead Healy
Trevor Robbins
Ana Frota Lisboa Pereira de Souza
Robin Tyacke
Maria Papasyrou
Dea Stenbæk
Pedro Castro-Rodrigues
Martina Chiera
Hakjun Lee
Jonny Martell
Robin Carhart-Harris
Luca Pellegrini
Naomi A Fineberg
David Nutt
David Erritzoe